Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2014 2
2016 1
2018 1
2019 1
2022 2
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS. O'Donnell EK, et al. Among authors: burke jn. Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8. Br J Haematol. 2018. PMID: 29740809 Free PMC article. Clinical Trial.
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Yee AJ, Laubach JP, Campagnaro EL, Lipe BC, Nadeem O, Friedman RS, Cole CE, O'Donnell EK, Bianchi G, Branagan AR, Schlossman RL, Shapiro SJ, Harrington CC, Burke JN, Gammon MT, Lively KJ, Reimonn CA, Andrade DX, Redd R, Lohr JG, Anderson KC, Richardson PG, Raje NS. Yee AJ, et al. Among authors: burke jn. Blood Adv. 2025 Mar 11;9(5):1163-1170. doi: 10.1182/bloodadvances.2024014717. Blood Adv. 2025. PMID: 39626297 Free PMC article. Clinical Trial.
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.
Branagan AR, Mo CC, Lei MM, Gustine J, Yee AJ, O'Donnell E, Castillo JJ, Nadeem O, Flynn C, Bernstein Z, Nakamoto-Matsubara R, Meid KE, Verma R, Hunter ZR, Guerrera ML, Alter G, Burke JN, Harrington CC, Agyemang EA, Gammon MT, Lively KJ, Packer L, Horick N, Laubach JP, Mitsiades CS, Munshi NC, Anderson KC, Treon SP, Richardson PG, Raje NS, Sarosiek S. Branagan AR, et al. Among authors: burke jn. Blood Adv. 2025 Jun 5:bloodadvances.2025016513. doi: 10.1182/bloodadvances.2025016513. Online ahead of print. Blood Adv. 2025. PMID: 40472329
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.
O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Richardson PG, Raje NS, El-Jawahri A. O'Donnell EK, et al. Among authors: burke jn. Cancer. 2022 May 15;128(10):1996-2004. doi: 10.1002/cncr.34134. Epub 2022 Feb 15. Cancer. 2022. PMID: 35167125 Free article.
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma.
O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Hu BY, Richardson PG, Raje NS, El-Jawahri A. O'Donnell EK, et al. Among authors: burke jn. Blood Adv. 2022 Sep 13;6(17):4967-4974. doi: 10.1182/bloodadvances.2022007127. Blood Adv. 2022. PMID: 35848842 Free PMC article.
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ, Bensinger WI, Supko JG, Voorhees PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE, Burke JN, Tamang DL, Yang M, Jones SS, Wheeler CA, Markelewicz RJ, Raje NS. Yee AJ, et al. Among authors: burke jn. Lancet Oncol. 2016 Nov;17(11):1569-1578. doi: 10.1016/S1470-2045(16)30375-8. Epub 2016 Sep 17. Lancet Oncol. 2016. PMID: 27646843 Clinical Trial.
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS. Yee AJ, et al. Among authors: burke jn. Br J Haematol. 2014 Aug;166(3):401-9. doi: 10.1111/bjh.12909. Epub 2014 Apr 25. Br J Haematol. 2014. PMID: 24761838 Clinical Trial.
12 results